Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-12-13Clinical Trial Update: Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) [Phase 2]
Phase 2 trial investigating a glycine uptake inhibitor as adjuvant treatment for negative symptoms in schizophrenia has completed with resul…
-
CLINICAL_TRIALS research · 2016-12-08Clinical Trial Update: Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs [NA]
A clinical trial update examining how magnesium variations relate to cardiometabolic risk in patients taking antipsychotic medications.
-
CLINICAL_TRIALS trial_result · 2016-12-07Clinical Trial Update: Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) [Phase 2]
Phase 2 clinical trial of preladenant for antipsychotic-induced movement disorders in schizophrenia has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-12-01Clinical Trial Update: To Rescue Cognition With Valaciclovir [Phase 2]
Phase 2 clinical trial update on valaciclovir for cognitive rescue in schizophrenia/psychosis has completed.
-
FDA approval · 2016-11-29FDA Approved: CLOZAPINE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma's generic Clozapine under an original ANDA, authorizing its use as a treatment for schizophrenia (including tr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-11-29Clinical Trial Update: Yoga as Cognitive Remediation in Schizophrenia [NA]
A completed clinical trial evaluating yoga as cognitive remediation in schizophrenia.
-
FDA approval · 2016-11-28FDA Approved: ILOPERIDONE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved an original application for iloperidone by Mylan Pharmaceuticals, a generic antipsychotic indicated for schizophrenia.
-
CLINICAL_TRIALS research · 2016-11-28Clinical Trial Update: Factors Influencing Social Functioning of People With Schizophrenia
This entry reports a completed clinical trial studying factors that influence social functioning in people with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Upside Down, Give me the Handle [NA]
A clinical trial in schizophrenia sponsored by Centre Hospitalier Universitaire de Saint Étienne has completed.
-
FDA approval · 2016-11-18FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for RISPERDAL CONSTA (risperidone) from Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: The Impact of a Helplessness and Recovery of an Empowerment Intervention on People Diagnosed With Schizophrenia: Findings From a Randomized Controlled Trial [Phase 2]
Phase 2 randomized controlled trial evaluating an empowerment-based intervention designed to reduce helplessness and enhance recovery in peo…
-
FDA approval · 2016-11-18FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for fluphenazine decanoate filed by Endo USA, Inc., resulting in an approved regulatory action for t…
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: Assertive Community Treatment With CBT and SST for Schizophrenia [NA]
This document reports the completion of a clinical trial evaluating assertive community treatment combined with cognitive behavioral therapy…
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: Cognitive Remediation and Functional Skills Training in Schizophrenia [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating cognitive remediation and functional skills training for schizophrenia has completed. The study a…
-
CLINICAL_TRIALS research · 2016-11-16Clinical Trial Update: Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
A clinical trial update examining genetic polymorphisms and metabolic effects of second generation antipsychotics in people with schizophren…
-
CLINICAL_TRIALS research · 2016-11-10Clinical Trial Update: Neuroendocrine and Metabolite Substrates in Schizophrenia
Clinical trial update on neuroendocrine and metabolite substrates in schizophrenia sponsored by Chang Gung Memorial Hospital; current study …
-
CLINICAL_TRIALS trial_result · 2016-11-09Clinical Trial Update: Effects of Ketamine and Risperidone on Cognition [Phase 4]
A Phase 4 trial assessed the cognitive effects of ketamine and risperidone in healthy volunteers and individuals with schizophrenia and has …
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Safety and Efficacy of Zicronapine in Patients With Schizophrenia [Phase 3]
This Phase 3 trial evaluated the safety and efficacy of Zicronapine in patients with schizophrenia and is completed. The available excerpt d…
-
FDA approval · 2016-11-08FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for Fluphenazine Decanoate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Efficacy of Lu 31-130 in Patients With Schizophrenia [Phase 2]
This clinical trial update reports the efficacy results of Lu 31-130 in patients with schizophrenia in a Phase 2 study.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Efficacy of Lu 31-130 in Patients With Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating Lu 31-130 for schizophrenia has completed, reporting efficacy findings.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill [NA]
A completed clinical trial evaluating contingency management for stimulant use disorder in individuals with severe mental illness.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia [Phase 2]
Phase 2 efficacy study evaluating Lu AE58054 as augmentation therapy in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia [Phase 4]
A Phase 4 safety study of the antipsychotic Sertindole for schizophrenia has been completed.
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis [NA]
This ClinicalTrials.gov entry reports a completed study on multi-disciplinary treatment for patients experiencing a first episode of psychos…